IP Library › Granted Patent US 7,393,661

Granted Patent B2

US 7,393,661 · App. 11/132,814 · Granted Jul 1, 2008

Nucleic acids encoding OBG3 polypeptides

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,393,661
App. No.: 11/132,814
Granted: Jul 1, 2008
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. This application pertains to nucleic acids encoding a compound, globular OBG3 polypeptide fragments, vectors and transformed host cells containing these nucleic acids and methods of making the globular OBG3 polypeptide fragments.

Claims (132)

1. An isolated polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6, 99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6,191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6, amino acids 110 to 244 of SEQ ID NO: 6, amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added, or amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide that is complementary to said nucleic acid sequence.

2. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 87-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

3. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 88-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

4. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 89-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

5. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 90-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

6. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 91-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

7. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 92-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

8. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 93-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

9. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 94-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

10. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 95-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

11. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 96-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

12. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 97-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

13. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 98-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

14. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 99-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

15. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 100-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

16. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 111-191 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

17. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 144-199 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

18. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 191-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

19. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

20. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

21. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

22. The isolated polynucleotide according to claim 1 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

23. A composition comprising a carrier and a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6, 99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6, 191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6, amino acids 110 to 244 of SEQ ID NO: 6, amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added, or amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide that is complementary to said nucleic acid sequence.

24. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 87-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

25. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 88-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

26. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 89-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

27. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 90-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

28. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 91-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

29. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 92-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

30. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 93-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

31. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 94-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

32. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 95-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

33. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 96-244 of SEQ ID NO: 6 or a polynucleotide complementaly thereto.

34. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 97-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

35. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 98-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

36. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 99-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

37. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 100-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

38. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 111-191 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

39. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 144-199 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

40. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 191-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

41. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

42. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

43. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

44. The composition according to claim 23 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

45. A vector comprising a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6, 99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6, 191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6, amino acids 110 to 244 of SEQ ID NO: 6, amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added, or amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide that is complementary to said nucleic acid sequence.

46. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 87-244 of SEQ ID NO: 6 or a polynucleotide complementaly thereto.

47. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 88-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

48. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 89-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

49. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 90-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

50. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 91-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

51. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 92-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

52. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 93-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

53. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 94-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

54. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 95-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

55. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 96-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

56. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 97-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

57. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 98-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

58. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 99-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

59. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 100-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

60. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 111-191 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

61. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 144-199 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

62. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 191-244 of SEQ ID NO: 6or a polynucleotide complementary thereto.

63. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

64. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

65. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

66. The vector according to claim 45 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

67. A composition comprising a carrier and a vector comprising a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6, 99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6, 191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6, amino acids 110 to 244 of SEQ ID NO: 6, amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added, or amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide that is complementary to said nucleic acid sequence.

68. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 87-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

69. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 88-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

70. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 89-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

71. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 90-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

72. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 91-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

73. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 92-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

74. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 93-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

75. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 94-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

76. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 95-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

77. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 96-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

78. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 97-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

79. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 98-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

80. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 99-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

81. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 100-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

82. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 111-191 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

83. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 144-199 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

84. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 191-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

85. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 108-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

86. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

87. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

88. The composition according to claim 67 , wherein said vector comprises a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

89. An isolated transformed host cell comprising a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6,99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6, 191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6, amino acids 110 to 244 of SEQ ID NO: 6, amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added, or amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide that is complimentary to said nucleic acid sequence.

90. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 87-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

91. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 88-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

92. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 89-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

93. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 90-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

94. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 91-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

95. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 92-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

96. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 93-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

97. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 94-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

98. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 95-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

99. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 96-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

100. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 97-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

101. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 98-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

102. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 99-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

103. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 100-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

104. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 111-191 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

105. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 144-199 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

106. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 191-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

107. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

108. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

109. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

110. The isolated transformed host cell according to claim 89 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

111. A method of making a polypeptide comprising culturing a isolated transformed host cell comprising a polynucleotide consisting of a nucleic acid sequence encoding consecutive amino acids: 87-244 of SEQ ID NO: 6, 88-244 of SEQ ID NO: 6, 89-244 of SEQ ID NO: 6, 90-244 of SEQ ID NO: 6, 91-244 of SEQ ID NO: 6, 92-244 of SEQ ID NO: 6, 93-244 of SEQ ID NO: 6, 94-244 of SEQ ID NO: 6, 95-244 of SEQ ID NO: 6, 96-244 of SEQ ID NO: 6, 97-244 of SEQ ID NO: 6, 98-244 of SEQ ID NO: 6, 99-244 of SEQ ID NO: 6, 100-244 of SEQ ID NO: 6, 111-191 of SEQ ID NO: 6, 144-199 of SEQ ID NO: 6, 191-244 of SEQ ID NO: 6, 108 to 244 of SEQ ID NO: 6, amino acids 110 to 244 of SEQ ID NO: 6, amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added, or amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added under condition that allow for the expression of a polypeptide encoded by said polynucleotide.

112. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 87-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

113. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 88-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

114. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 89-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

115. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 90-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

116. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 91-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

117. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 92-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

118. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 93-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

119. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 94-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

120. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 95-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

121. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 96-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

122. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 97-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

123. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 98-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

124. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 99-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

125. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 100-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

126. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 111-191 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

127. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 144-199 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

128. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 191-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

129. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108-244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

130. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 108 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

131. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 to which an N-terminal methionine has been added or a polynucleotide complementary thereto.

132. The method according to claim 111 , wherein said polynucleotide consists of a nucleic acid sequence encoding consecutive amino acids 110 to 244 of SEQ ID NO: 6 or a polynucleotide complementary thereto.

Assignments (2)

CHANGE OF NAME Recorded Aug 3, 2005

From: GENSET S.A.

To: SERONO GENETICS INSTITUTE S.A.

Reel/Frame 016348/0865 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2005

From: FRUEBIS, JOACHIM; ERICKSON, MARY RUTH; BIHAIN, BERNARD; YEN-POTIN, FRANCES

To: GENSET S.A.

Reel/Frame 016432/0659 →